Equities

Viking Therapeutics Inc

Viking Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)68.16
  • Today's Change3.71 / 5.76%
  • Shares traded2.60m
  • 1 Year change+393.91%
  • Beta1.0090
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy7
Outperform6
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for Viking Therapeutics Inc have a median target of 118.00, with a high estimate of 138.00 and a low estimate of 90.00. The median estimate represents a 83.09% increase from the last price of 64.45.
High114.1%138.00
Med83.1%118.00
Low39.6%90.00

Earnings history & estimates in USD

On Jul 24, 2024, Viking Therapeutics Inc reported 2nd quarter 2024 losses of -0.20 per share. This result exceeded the -0.270 consensus loss of the 12 analysts covering the company and under-performed last year's 2nd quarter results by 5.26%.
The next earnings announcement is expected on Oct 23, 2024.
Average growth rate-2.67%
Viking Therapeutics Inc reported annual 2023 losses of -0.91 per share on Feb 07, 2024.
Average growth rate-27.34%
More ▼

Revenue history & estimates in USD

Viking Therapeutics, Inc. did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Viking Therapeutics, Inc. did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.